Explore the science behind your treatment
Get to know KOVALTRY
KOVALTRY is designed to stay close to your body’s natural FVIII
KOVALTRY is a full-length FVIII treatment. A full-length FVIII treatment has the same 6 sections as natural FVIII. It is also unmodified, meaning no other molecules have been added.1
Natural FVIII protein is composed of 6 main sections. KOVALTRY is full-length because it contains the same 6 sections.1,2
When natural FVIII and KOVALTRY are being made, sugar structures become attached to them.1,2
These sugar structures are then capped. Capping protects KOVALTRY from being removed by the body too early. Natural FVIII is also capped in this way.1,3,4
Natural FVIII and KOVALTRY both go through a process that prepares them to attach to a carrier protein, called von Willebrand factor.1,5,6
Von Willebrand factor carries KOVALTRY through the bloodstream and keeps it from being broken down. Natural FVIII is also carried through the bloodstream in this way.1
How does KOVALTRY treatment work?
KOVALTRY is an unmodified, full-length antihemophilic FVIII recombinant product, designed to closely match your body's natural Factor FVIII. Watch this video to learn about how KOVALTRY works in your bloodstream.
How does KOVALTRY treatment work?
KOVALTRY is an unmodified, full-length antihemophilic FVIII recombinant product, designed to closely match your body's natural Factor FVIII. Watch this video to learn about how KOVALTRY works in your bloodstream.
See how KOVALTRY is made
KOVALTRY is manufactured using recombinant DNA technology, with the support of more than 1,000 Bayer scientists and technicians. Check out this video explaining the science of KOVALTRY and how it is made and manufactured in our Berkeley, CA laboratory.
See how KOVALTRY is made
KOVALTRY is manufactured using recombinant DNA technology, with the support of more than 1,000 Bayer scientists and technicians. Check out this video explaining the science of KOVALTRY and how it is made and manufactured in our Berkeley, CA laboratory.
INDICATION FOR KOVALTRY®
KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.
KOVALTRY is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY when you have surgery.
KOVALTRY is not used to treat von Willebrand Disease.
IMPORTANT SAFETY INFORMATION
You should not use KOVALTRY if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY.
Tell your healthcare provider if you have heart disease or are at risk for heart disease.
The common side effects of KOVALTRY are fever, headache, and rash, in addition to inhibitors in patients who were not previously treated or minimally treated with Factor VIII products.
Your body may make antibodies, called “inhibitors” against KOVALTRY, which may stop KOVALTRY from working properly. If your bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.
Allergic reactions may occur with KOVALTRY. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.
Tell your healthcare provider about any side effect that bothers you or that does not go away.
Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY.
For additional important risk and use information, please see full Prescribing Information.
References: 1. KOVALTRY [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2021. 2. Pipe SW. Functional roles of the factor VIII domain. Haemophilia. 2009;15[6]:1187-1196. 3. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor—too sweet for their own good. Haemophilia. 2010;16[suppl 5]:194-199. 4. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BMJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005;3[6]:1257-1265. 5. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92[11]:3983-3996. 6. Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem. 1991;266[2]:740-746.
